- Home
- TRVI vs JFR Comparison
TRVI vs JFR Comparison
Compare TRVI & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- JFR
- Stock Information
- Founded
- TRVI 2011
- JFR 2004
- Country
- TRVI United States
- JFR United States
- Employees
- TRVI N/A
- JFR N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- TRVI Health Care
- JFR Finance
- Exchange
- TRVI Nasdaq
- JFR Nasdaq
- Market Cap
- TRVI 1.4B
- JFR 1.3B
- IPO Year
- TRVI 2019
- JFR N/A
- Fundamental
- Price
- TRVI $13.34
- JFR $7.89
- Analyst Decision
- TRVI Strong Buy
- JFR
- Analyst Count
- TRVI 11
- JFR 0
- Target Price
- TRVI $20.59
- JFR N/A
- AVG Volume (30 Days)
- TRVI 1.8M
- JFR 621.7K
- Earning Date
- TRVI 11-13-2025
- JFR 01-01-0001
- Dividend Yield
- TRVI N/A
- JFR 11.31%
- EPS Growth
- TRVI N/A
- JFR N/A
- EPS
- TRVI N/A
- JFR N/A
- Revenue
- TRVI N/A
- JFR N/A
- Revenue This Year
- TRVI N/A
- JFR N/A
- Revenue Next Year
- TRVI N/A
- JFR N/A
- P/E Ratio
- TRVI N/A
- JFR N/A
- Revenue Growth
- TRVI N/A
- JFR N/A
- 52 Week Low
- TRVI $2.36
- JFR $7.61
- 52 Week High
- TRVI $13.73
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- TRVI 72.54
- JFR 48.68
- Support Level
- TRVI $10.46
- JFR $7.94
- Resistance Level
- TRVI $12.14
- JFR $7.80
- Average True Range (ATR)
- TRVI 0.79
- JFR 0.06
- MACD
- TRVI 0.06
- JFR 0.01
- Stochastic Oscillator
- TRVI 92.05
- JFR 61.67
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.